This is a working overview of research compound, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
But he believed that this Federation could not be done without dividing Peru again, since the other countries ran the risk of being more easily dominated by Peru, being economically weaker at the time. That was how he decided to separate Peru in two again, segregating the southern departments to form another republic. The legal framework that would unite the countries of the Federation would be the "Constitución Vitalicia" [Life Constitution] that Bolívar drafted for Bolivia, and that he would send to the Congress of Peru for its approval and later to that of Greater Colombia. In Lima there was a strong rejection of this alleged way of reunifying both societies in a federation of 3 states (consisting of Bolivia and a Peru divided into north and south), and it was predicted that the country would later be dominated by the leadership of Bogotá with the Bolivar's confederation project. To achieve the separation of southern Peru, Bolívar had the support of the prefects (regional governors) of those departments, especially that of Arequipa, the military and politician Antonio Gutiérrez de la Fuente, laying the foundations for future Arequipa separatism in Peru. Thus, Andres de Santa Cruz sent a letter to La Fuente in which he informed him that, according to reliable anonymous testimony from the Republic of Bolívar, he was aware that Puno, Arequipa and Cuzco sought to make southern Peru independent and thus separate "from the respectable Peruvian nation".
== History == Cloud laboratories were built on advancements made in laboratory automation in the 1990s. In the early 1990s, the modularity project of the Consortium of Automated Analytical Laboratory Systems worked to define standards by which biotechnology manufacturers could produce products that could be integrated into automated systems. In 1996, the National Committee for Clinical Laboratory Standards (now the Clinical and Laboratory Standards Institute) proposed laboratory automation standards that aimed to enable consumers of laboratory technology to purchase hardware and software from different vendors and connect them to each other seamlessly. The committee launched five subcommittees in 1997 and released standardization protocols to guide product development through the early 2000s. These early developments in interoperability led to early examples of lab automation using cloud infrastructure, such as the Robot Scientist "Adam" in 2009. This robot encapsulated and connected all the laboratory equipment necessary to perform microbial batch experiments. In 2010, D. J. Kleinbaum and Brian Frezza founded antiviral developer Emerald Therapeutics. To simplify laboratory testing, the group wrote centralized management software for their collection of scientific instruments and a database to store all metadata and results. In 2012, Transcriptic founded a robotic cloud laboratory for on-demand scientific research, which performed select tasks including DNA cloning remotely.
== History == L.W. Alvarez and Robert Cornog of the United States first used an accelerator as a mass spectrometer in 1939 when they employed a cyclotron to demonstrate that 3He was stable; from this observation, they immediately and correctly concluded that the other mass-3 isotope, tritium (3H), was radioactive. In 1977, inspired by this early work, Richard A. Muller at the Lawrence Berkeley Laboratory recognised that modern accelerators could accelerate radioactive particles to an energy where the background interferences could be separated using particle identification techniques. He published the seminal paper in Science showing how accelerators (cyclotrons and linear) could be used for detection of tritium, radiocarbon (14C), and several other isotopes of scientific interest including 10Be; he also reported the first successful radioisotope date experimentally obtained using tritium. His paper was the direct inspiration for other groups using cyclotrons (G. Raisbeck and F. Yiou, in France) and tandem linear accelerators (D. Nelson, R. Korteling, W. Stott at McMaster). K. Purser and colleagues also published the successful detection of radiocarbon using their tandem at Rochester. Soon afterwards the Berkeley and French teams reported the successful detection of 10Be, an isotope widely used in geology. Soon the accelerator technique, since it was more sensitive by a factor of about 1,000, virtually supplanted the older "decay counting" methods for these and other radioisotopes. In 1982, AMS labs began processing archaeological samples for radiocarbon dating
Sources: en.wikipedia.org
Pre-formed mediators stored in granules biogenic amines (histamine, serotonin, dopamine) proteases (serine proteases including tryptase and chymase, aspartic acid proteases, cysteine proteases, metalloproteinases including CPA3) proteoglycans (heparin, chondroitin sulfate) cytokines (TNF, IL-4) growth factors (GM-CSF, bFGF, VEGF, NGF) lysosomal enzymes (β-hexosaminidase, β-glucuronidase, CD63) Newly synthesized inflammatory mediators lipid mediators (eicosanoids, thromboxane, LTB4, LTC4, PAF, PGD2) neuropeptides (CRH, VIP) growth factors (PDGF, GnRH) chemokines (MCP-1, eotaxin, TARC, RANTES) cytokines (IL-1, IL-3, IL-6, IL-18, SCF, TGF-β)
Protolichesterinic acid is a naturally occurring γ-lactone compound found in various lichen species. Its structure consists of a combination of a lactone ring with a carboxylic acid group and a long aliphatic side chain. First isolated in the early 20th century, protolichesterinic acid has drawn scientific interest due to its diverse biological activities, including antimicrobial, antifungal, and anti-inflammatory properties. It is also noted for its potential as a therapeutic agent, particularly as a selective inhibitor of the 5-lipoxygenase enzyme, which is implicated in inflammatory diseases. Protolichesterinic acid is typically extracted from lichens such as Cetraria islandica using advanced chromatographic techniques and has been studied for its role in both natural product chemistry and pharmacology.
Brindisi Limonta insisted that his disbarment was illegal, because Valdés García should have recused himself from the case to begin with. Many Cuban Freemasons considered this as an act of retribution by Urquía Carreño, and questioned the legality of the Supreme Court's decision, because Urquía Carreño was in violation of his own expulsion at the time of the sentencing. They alleged that Urquía Carreño was either complicit in the theft or was attempting to cause a distraction so that people would stop asking about the stolen Llansó money. They also noted that the outcome document's lack of signatures or seals indicated that the expulsion was not legally binding. On March 19, 2024, Pompilio Portuondo, a Cuban Freemason on an exchange program with the Grand Lodge of Colombia, wrote on Facebook that he believed a grand conspiracy was taking place in Cuba to cover up the theft. He wrote that certain members of the Grand Lodge were either complicit in the coverup or directly responsible for the theft; Grand Secretary Misiel Hernandez Peraza was alleged to be an active agent in Military Intelligence, Grand Treasurer Airam Cervera Reigosa was allegedly an accomplice in the robbery, Supreme Court of Masonic Justice President Ernesto Valdés García, Yamil Valiente, accountant Rolando Mena, Calos Lorenzo Perez, and Magistrate of the Supreme Court of Masonic Justice Inti Paneca were also all allegedly involved in the plot. He requested that any Lodge in Florida or anywhere else in the United States deny these men asylum or membership in their Lodges.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.